G20.00
Conditions
Interventions
Group 1: treatment with 1 mg of vitamin K2 (MK-7) on a daily basis for seven days
Group 2: placebo
Sponsors
Universitätsklinikum Schleswig-Holstein, Campus Lübeck
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age =18 years; written informed consent; PD diagnosis based on MDS criteria (if applicable); stable PD medication (if applicable)
Exclusion criteria
Exclusion criteria: comorbidities that might impair informed consent; MRI contraindications or structural brain diseases (e. g. stroke); atypical or secondary parkinsonism; unstable PD medication (if applicable); known allergy/intolerance to vitamin K2; treatment with vitamin K2 or vitamin K-antagonist one month prior to the start of this trial; chronic GI malabsorption (e.g. celiac disease, short bowel syndrome); ongoing malignancy; abuse of alcohol or other euphoric drug; women who are pregnant or breast-feeding; total/subtotal parathyroidectomy; treatment with recombined parathormone; treatment with bisphosphonates (or other anti-osteoporotic drugs); treatment with statins
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Magnetic resonance spectroscopic measurement of adenosine triphosphate and phosphocreatine (normalized for inorganic phosphate) pre- and postinterventionally after one-week treatment with vitamin K2 (1 mg/d for a total of seven days) compared with placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| n. a. | — |
Countries
Germany
Contacts
Public ContactNorbert Brüggemann
Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Campus LübeckInstitut für Neurogenetik,Universität zu Lübeck
Outcome results
None listed